Genenta Science S.p.A. — Investor Relations & Filings
Genenta Science is a clinical-stage company developing immuno-oncology therapies based on a proprietary hematopoietic stem cell (HSC) gene therapy platform. The company's technology is designed to reprogram the tumor microenvironment, making solid tumors visible to the immune system and breaking immune tolerance. Its lead candidate, Temferon, aims to deliver therapeutics directly within the tumor mass. The treatment is being investigated as a potential one-time monotherapy and in combination with other approved therapeutics, such as immune checkpoint inhibitors. Clinical development includes a completed Phase 1 trial for Glioblastoma Multiforme and an ongoing Phase 1/2a study in metastatic Renal Cell Carcinoma.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 6-K | 2026-05-29 | English | |
| 6-K | 2026-05-19 | English | |
| 6-K - Genenta Science S.p.A. (0001838716) (Filer) | 2026-03-27 | English | |
| 3 - Genenta Science S.p.A. (0001838716) (Issuer) | 2026-03-18 | English | |
| 3 - Genenta Science S.p.A. (0001838716) (Issuer) | 2026-03-18 | English | |
| 3 - Genenta Science S.p.A. (0001838716) (Issuer) | 2026-03-18 | English |
Browse filings by year
6 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
8 filings
| |||||
| 47893721 | 6-K | 2026-05-29 | English | ||
| 46559661 | 6-K | 2026-05-19 | English | ||
| 33057481 | 6-K - Genenta Science S.p.A. (0001838716) (Filer) | 2026-03-27 | English | ||
| 32979435 | 3 - Genenta Science S.p.A. (0001838716) (Issuer) | 2026-03-18 | English | ||
| 32979131 | 3 - Genenta Science S.p.A. (0001838716) (Issuer) | 2026-03-18 | English | ||
| 32979121 | 3 - Genenta Science S.p.A. (0001838716) (Issuer) | 2026-03-18 | English | ||
| 32005936 | 6-K Filing | 2026-01-27 | English | ||
| 32005934 | 6-K Filing | 2026-01-27 | English | ||
|
2025
7 filings
| |||||
| 13358583 | 6-K | 2025-11-03 | English | ||
| 13358584 | 424B5 | 2025-10-28 | English | ||
| 13358585 | 6-K | 2025-10-28 | English | ||
| 13358586 | 6-K | 2025-10-27 | English | ||
| 13358590 | 6-K | 2025-10-10 | English | ||
| 13358587 | 6-K | 2025-10-03 | English | ||
| 13358591 | 6-K | 2025-09-10 | English | ||
Financials
We couldn't load the financials
No data available yet
We have extracted financials for Genenta Science S.p.A., but not for this combination of statement and period. Try a different combination.
Swipe the table to view all periods, or rotate your phone for a wider view.
| Line item | ! |
|---|---|
| Definition not yet available — coming soon. |
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
NOXOPHARM LIMITED
Clinical-stage developer of novel treatments for cancer and…
|
NOX | AU | Professional, scientific and te… |
|
NUFORMIX PLC
Pharmaceutical developer using cocrystal technology to repu…
|
NFX | GB | Professional, scientific and te… |
|
Nurix Therapeutics, Inc.
Clinical-stage biopharma developing protein degradation the…
|
NRIX | US | Professional, scientific and te… |
|
NYRADA INC.
Develops small molecule therapeutics for cardiovascular hea…
|
NYR | AU | Professional, scientific and te… |
|
OLIPASS CORPORATION
An R&D company developing RNA therapeutics using its propri…
|
244460 | KR | Professional, scientific and te… |
|
OmniAb, Inc.
A technology platform for therapeutic antibody discovery us…
|
OABIW | US | Professional, scientific and te… |
|
ONCIMMUNE HOLDINGS PLC
Immunodiagnostics company specializing in antibody and auto…
|
ONC | GB | Professional, scientific and te… |
|
Oncocross Co.,Ltd.
An AI biotechnology firm that develops drugs by predicting …
|
382150 | KR | Professional, scientific and te… |
|
ONCODESIGN
Develops therapeutic and diagnostic solutions for resistant…
|
ALONC | FR | Professional, scientific and te… |
|
Onco-Innovations
Biotechnology firm developing next-generation cancer therap…
|
ONCO | CA | Professional, scientific and te… |
Genenta Science S.p.A. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34499/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34499 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34499 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34499 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34499}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Genenta Science S.p.A. (id: 34499)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.